Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Cantor Fitzgerald
Federal Trade Commission
UBS
Julphar
Cipla
Johnson and Johnson
Colorcon
US Department of Justice
Healthtrust

Generated: December 15, 2018

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR TICLOPIDINE HYDROCHLORIDE

« Back to Dashboard

Clinical Trials for Ticlopidine Hydrochloride

Trial ID Title Status Sponsor Phase Summary
NCT00004727 Antiplatelet Therapy to Prevent Stroke in African Americans Completed National Institute of Neurological Disorders and Stroke (NINDS) Phase 4 The African-American Antiplatelet Stroke Prevention Study is designed to prevent recurrent strokes by administration of aspirin or ticlopidine. The study also provides community information on reducing risk of stroke and recognizing the symptoms of stroke. The study involves more than 50 participating hospitals located throughout the United States. Study medication is provided free of charge, and a transportation stipend is available for those in need.
NCT00069069 E-Selectin Nasal Instillation to Prevent Secondary Stroke Not yet recruiting National Institute of Neurological Disorders and Stroke (NINDS) Phase 1 This study will determine the maximum safe dose of the experimental drug E-selectin that can be given to stroke patients. E-selectin causes white blood cells called lymphocytes to change so that they prevent clots from forming in the vessels that supply blood to the brain. The drug has been shown to be effective in animal models of stroke. This study will look at the safety of using this experimental drug in nasal instillation form in patients who have had a stroke or transient ischemic attack (TIA). Patients 45 years of age or older who have had a recent stroke or TIA (30 to 120 days before entering the study) due to a clot forming in a vessel that supplies blood to the brain may be eligible for this study. They must be taking at least one medication to prevent clots, such as coumadin, aspirin, ticlopidine, or others. Candidates will be screened with a physical and neurological examination, blood and urine tests, electrocardiogram (EKG), echocardiogram (ultrasound test of the heart), and magnetic resonance imaging (MRI) of the brain. Participants will be randomly assigned to receive E-selectin at a dose level of 5, 15, or 50 micrograms or a placebo (nasal drops with no active ingredient). They will instill a small, carefully premeasured amount (one dose) of fluid in their nose every other day for 10 days (total of 5 doses). This course of treatment will be repeated two times at 3-week intervals. Patients will be followed at 1 month and 3 months with a neurologic examination and blood and urine tests. They will be contacted by phone, fax, or email in between these two visits.
NCT00133003 Abciximab, Clopidogrel and Percutaneous Coronary Intervention in Acute Coronary Syndrome (ISAR-REACT-2) Completed Technische Universität München Phase 4 The purpose of this study is to determine whether there is any additional benefit from abciximab administration during percutaneous coronary intervention in patients presenting with acute coronary syndromes after pre-treatment with 600mg of clopidogrel.
NCT00133003 Abciximab, Clopidogrel and Percutaneous Coronary Intervention in Acute Coronary Syndrome (ISAR-REACT-2) Completed Deutsches Herzzentrum Muenchen Phase 4 The purpose of this study is to determine whether there is any additional benefit from abciximab administration during percutaneous coronary intervention in patients presenting with acute coronary syndromes after pre-treatment with 600mg of clopidogrel.
NCT00262054 Un-fractionated Heparin Versus Bivalirudin During Percutaneous Coronary Interventions (PCI) (ISAR-REACT-3) Completed Deutsches Herzzentrum Muenchen Phase 4 The purpose of this study is to determine whether bivalirudin given during PCI is associated with better outcomes compared to un-fractionated heparin.
NCT00325390 Efficacy and Safety in Patients With Acute Coronary Syndrome Without ST-Segment Elevation Completed Daiichi Pharmaceuticals Phase 3 To evaluate the efficasy and safety of SR25990C(loading dose:300mg, maintenance dose:75mg/day) in comparison with the standard Japanese treatment(ticlopidine) in patients with acute coronary syndrome without ST-segment elevation and planned for percutaneous coronary intervention(including stenting).
Trial ID Title Status Sponsor Phase Summary

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Clinical Trial Conditions for Ticlopidine Hydrochloride

Condition Name

Condition Name for Ticlopidine Hydrochloride
Intervention Trials
Coronary Artery Disease 12
Renal Artery Stenosis 2
Coronary Disease 2
Peptic Ulcer 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Ticlopidine Hydrochloride
Intervention Trials
Coronary Disease 14
Coronary Artery Disease 14
Myocardial Ischemia 12
Infarction 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Ticlopidine Hydrochloride

Trials by Country

Trials by Country for Ticlopidine Hydrochloride
Location Trials
United States 81
Japan 18
Italy 9
Germany 4
Belgium 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Ticlopidine Hydrochloride
Location Trials
New York 5
California 4
Michigan 4
Missouri 3
Florida 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Ticlopidine Hydrochloride

Clinical Trial Phase

Clinical Trial Phase for Ticlopidine Hydrochloride
Clinical Trial Phase Trials
Phase 4 21
Phase 3 7
Phase 2/Phase 3 1
[disabled in preview] 10
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Ticlopidine Hydrochloride
Clinical Trial Phase Trials
Completed 21
Unknown status 10
Not yet recruiting 3
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Ticlopidine Hydrochloride

Sponsor Name

Sponsor Name for Ticlopidine Hydrochloride
Sponsor Trials
Boston Scientific Corporation 4
Sanofi 3
Deutsches Herzzentrum Muenchen 3
[disabled in preview] 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Ticlopidine Hydrochloride
Sponsor Trials
Other 32
Industry 14
NIH 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Express Scripts
Baxter
Daiichi Sankyo
Accenture
Dow
Chinese Patent Office
Cantor Fitzgerald
AstraZeneca
Queensland Health

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.